JP7646213B2 - がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞 - Google Patents

がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞 Download PDF

Info

Publication number
JP7646213B2
JP7646213B2 JP2021562641A JP2021562641A JP7646213B2 JP 7646213 B2 JP7646213 B2 JP 7646213B2 JP 2021562641 A JP2021562641 A JP 2021562641A JP 2021562641 A JP2021562641 A JP 2021562641A JP 7646213 B2 JP7646213 B2 JP 7646213B2
Authority
JP
Japan
Prior art keywords
eso
cells
cell
aavc
cd1d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562641A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021112055A5 (https=
JPWO2021112055A1 (https=
Inventor
彩佳 秋葉
達也 奥平
泰英 増原
恵介 大隅
眞一郎 藤井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Publication of JPWO2021112055A1 publication Critical patent/JPWO2021112055A1/ja
Publication of JPWO2021112055A5 publication Critical patent/JPWO2021112055A5/ja
Application granted granted Critical
Publication of JP7646213B2 publication Critical patent/JP7646213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021562641A 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞 Active JP7646213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019217704 2019-12-02
JP2019217704 2019-12-02
PCT/JP2020/044586 WO2021112055A1 (ja) 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞

Publications (3)

Publication Number Publication Date
JPWO2021112055A1 JPWO2021112055A1 (https=) 2021-06-10
JPWO2021112055A5 JPWO2021112055A5 (https=) 2023-10-30
JP7646213B2 true JP7646213B2 (ja) 2025-03-17

Family

ID=76222293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562641A Active JP7646213B2 (ja) 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞

Country Status (21)

Country Link
US (2) US11672851B2 (https=)
EP (1) EP4071240A4 (https=)
JP (1) JP7646213B2 (https=)
KR (1) KR20220119030A (https=)
CN (1) CN114787344A (https=)
AR (1) AR120648A1 (https=)
AU (1) AU2020394993A1 (https=)
BR (1) BR112022010763A2 (https=)
CA (1) CA3162277A1 (https=)
CL (1) CL2022001459A1 (https=)
CO (1) CO2022008738A2 (https=)
CR (1) CR20220320A (https=)
DO (1) DOP2022000108A (https=)
EC (1) ECSP22049399A (https=)
IL (1) IL293482A (https=)
JO (1) JOP20220121A1 (https=)
MX (1) MX2022006716A (https=)
PE (1) PE20221463A1 (https=)
PH (1) PH12022551334A1 (https=)
TW (1) TW202134431A (https=)
WO (1) WO2021112055A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
WO2025230010A1 (ja) * 2024-05-02 2025-11-06 国立研究開発法人理化学研究所 ＣＤ１ｄ導入前にＣＤ１ｄリガンドでインキュベートされた細胞

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097370A1 (ja) 2006-02-22 2007-08-30 Riken ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
WO2010061930A1 (ja) 2008-11-28 2010-06-03 独立行政法人理化学研究所 CD1d及び標的抗原の共発現アロ細胞を用いた免疫療法
JP2018521674A (ja) 2015-07-31 2018-08-09 シンロジック オペレーティング カンパニー インコーポレイテッド プロピオネート異化を伴う障害を治療するために操作された細菌

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
WO2008057795A2 (en) * 2006-10-27 2008-05-15 Temple University - Of The Commonwealth System Of Higher Education Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
BR112012024375A2 (pt) 2010-03-25 2016-05-24 3M Innovative Properties Co camada compósita
EP2738253A4 (en) 2011-07-29 2015-04-22 Riken CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097370A1 (ja) 2006-02-22 2007-08-30 Riken ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
WO2010061930A1 (ja) 2008-11-28 2010-06-03 独立行政法人理化学研究所 CD1d及び標的抗原の共発現アロ細胞を用いた免疫療法
JP2018521674A (ja) 2015-07-31 2018-08-09 シンロジック オペレーティング カンパニー インコーポレイテッド プロピオネート異化を伴う障害を治療するために操作された細菌

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAHIPAL, A et al.，Cancer Immunology, Immunotherapy，2019年05月08日，Vol.68，p.1211-1222
白畑實隆 他，SB-2p-3 汎用高発現動物宿主細胞・ベクター系の開発，日本農芸化学会大会講演要旨集，７４巻臨時増刊号，社団法人 日本農芸化学会，2000年，p.469

Also Published As

Publication number Publication date
US11672851B2 (en) 2023-06-13
JOP20220121A1 (ar) 2022-05-23
CL2022001459A1 (es) 2023-02-24
MX2022006716A (es) 2022-09-12
EP4071240A4 (en) 2024-01-17
KR20220119030A (ko) 2022-08-26
DOP2022000108A (es) 2022-10-31
US20230330200A1 (en) 2023-10-19
WO2021112055A1 (ja) 2021-06-10
AR120648A1 (es) 2022-03-09
CA3162277A1 (en) 2021-06-10
JPWO2021112055A1 (https=) 2021-06-10
EP4071240A1 (en) 2022-10-12
US20230000965A1 (en) 2023-01-05
TW202134431A (zh) 2021-09-16
BR112022010763A2 (pt) 2022-08-23
CN114787344A (zh) 2022-07-22
ECSP22049399A (es) 2022-08-31
PE20221463A1 (es) 2022-09-21
IL293482A (en) 2022-08-01
PH12022551334A1 (en) 2023-11-20
AU2020394993A1 (en) 2022-06-09
CO2022008738A2 (es) 2022-07-19
CR20220320A (es) 2022-11-03

Similar Documents

Publication Publication Date Title
US20240226157A1 (en) Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune Function
US20240139248A1 (en) Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19
JP2024507929A (ja) 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
JP2021523090A (ja) 腫瘍を治療するための方法および組成物
US20230381305A1 (en) METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)
US20230330200A1 (en) Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer
WO2021206104A1 (ja) がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
WO2023249071A1 (ja) Ｔ細胞受容体
HK40030365A (en) Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19
BR122024018798A2 (pt) Vetor de expressão para gerar uma célula imunocompetente, métodos para preparar uma célula imunocompetente e uso de uma célula imunocompetente

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250226

R150 Certificate of patent or registration of utility model

Ref document number: 7646213

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150